Glatz Andrew C, Keashen Rachel, Chang Julie, Balsama Lisa-Ann, Dori Yoav, Gillespie Matthew J, Giglia Therese M, Raffini Leslie, Rome Jonathan J
Division of Cardiology, Children's Hospital of Philadelphia; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania.
Catheter Cardiovasc Interv. 2015 Jan 1;85(1):111-7. doi: 10.1002/ccd.25686. Epub 2014 Oct 7.
Objectives To describe the results of a clinical practice pathway (CPP) for the management of postcatheterization pulse loss in a children's hospital.
Standardized approaches to the diagnosis and management of postcatheterization arterial thrombus are lacking. As a result, substantial practice variation exists.
Data collected prospectively for quality improvement purposes were retrospectively reviewed.
Since initiation of the CPP, 93/1,672 (5.4%) catheterizations resulted in pulse loss at a median patient age and weight of 73 days (1 day-5.8 years) and 4.8 kg (2-14.1 kg). Arterial thrombus was documented by ultrasound (US) in 85. Of these, 66 resolved by 12 weeks of therapy, seven patients died, and four were lost to follow-up before completing treatment. Eight patients had persistent thrombus despite a full treatment course (89% success rate in those able to complete treatment). Of patients treated with unfractionated heparin as initial therapy, 46% (17/37) achieved a therapeutic partial thromboplastin time within 12 hr with 19% (67/343) of all levels therapeutic. As a result, the CPP was modified to use enoxaparin as first line agent, of which 57% (41/72) had a therapeutic anti-Xa level after the 2nd dose and 88% by the 4th dose. No bleeding complications were observed. A priori established process metrics were achieved.
A CPP utilizing early initiation of anticoagulation and US to aid diagnosis of postcatheterization arterial thrombus and response to therapy is feasible and effective. In those able to complete up to 12 weeks of treatment, resolution occurs in nearly 90%. © 2014 Wiley Periodicals, Inc.
描述一家儿童医院用于处理导尿后脉搏消失的临床实践路径(CPP)的结果。
目前缺乏用于诊断和处理导尿后动脉血栓的标准化方法。因此,实际操作存在很大差异。
对为质量改进目的而前瞻性收集的数据进行回顾性分析。
自启动CPP以来,1672例导尿中有93例(5.4%)出现脉搏消失,患者年龄中位数为73天(1天至5.8岁),体重中位数为4.8千克(2至14.1千克)。超声(US)检查发现85例存在动脉血栓。其中,66例在治疗12周后血栓溶解,7例患者死亡,4例在完成治疗前失访。8例患者尽管接受了全程治疗仍有持续性血栓(能够完成治疗的患者成功率为89%)。以普通肝素作为初始治疗的患者中,46%(17/37)在12小时内达到治疗性部分凝血活酶时间,所有检测水平中有19%(67/343)达到治疗水平。因此,CPP修改为以依诺肝素作为一线药物,其中57%(')在第2剂后达到治疗性抗Xa水平,88%在第4剂后达到该水平。未观察到出血并发症。实现了预先设定的过程指标。
利用早期启动抗凝治疗和超声来辅助诊断导尿后动脉血栓及评估治疗反应的CPP是可行且有效的。在能够完成长达12周治疗的患者中,近90%的血栓会溶解。© 2014威利期刊公司